Financial Life Planners Invests $130,000 in Danaher Co. (NYSE:DHR)

Financial Life Planners bought a new position in Danaher Co. (NYSE:DHR) during the fourth quarter, according to the company in its most recent filing with the SEC. The firm bought 564 shares of the conglomerate’s stock, valued at approximately $130,000.

Other institutional investors also recently bought and sold shares of the company. FMR LLC raised its stake in shares of Danaher by 15.8% during the third quarter. FMR LLC now owns 23,617,424 shares of the conglomerate’s stock valued at $6,566,116,000 after acquiring an additional 3,217,631 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of Danaher by 3.0% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,097,986 shares of the conglomerate’s stock worth $1,417,342,000 after buying an additional 148,251 shares during the last quarter. Fisher Asset Management LLC increased its stake in shares of Danaher by 2.6% during the third quarter. Fisher Asset Management LLC now owns 4,552,640 shares of the conglomerate’s stock valued at $1,265,725,000 after buying an additional 116,299 shares during the period. Massachusetts Financial Services Co. MA increased its position in Danaher by 17.6% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 3,582,982 shares of the conglomerate’s stock valued at $996,141,000 after purchasing an additional 535,254 shares during the period. Finally, Montrusco Bolton Investments Inc. boosted its stake in shares of Danaher by 0.6% during the 4th quarter. Montrusco Bolton Investments Inc. now owns 1,715,826 shares of the conglomerate’s stock valued at $382,936,000 after purchasing an additional 9,942 shares in the last quarter. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Danaher

In other Danaher news, SVP Brian W. Ellis sold 5,700 shares of the firm’s stock in a transaction dated Thursday, January 30th. The shares were sold at an average price of $224.13, for a total value of $1,277,541.00. Following the completion of the sale, the senior vice president now owns 20,230 shares of the company’s stock, valued at $4,534,149.90. This trade represents a 21.98 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 10.90% of the stock is owned by company insiders.

Danaher Trading Down 0.2 %

Danaher stock opened at $222.56 on Monday. The firm has a market capitalization of $160.75 billion, a price-to-earnings ratio of 42.15, a P/E/G ratio of 2.80 and a beta of 0.83. Danaher Co. has a 12-month low of $221.34 and a 12-month high of $281.70. The firm has a 50 day moving average of $235.40 and a 200 day moving average of $253.09. The company has a current ratio of 1.40, a quick ratio of 1.05 and a debt-to-equity ratio of 0.31.

Danaher (NYSE:DHR) last released its quarterly earnings data on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share for the quarter, hitting analysts’ consensus estimates of $2.14. Danaher had a return on equity of 10.82% and a net margin of 16.33%. During the same period last year, the business earned $2.09 earnings per share. As a group, research analysts predict that Danaher Co. will post 7.77 earnings per share for the current year.

Danaher Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, January 31st. Investors of record on Friday, December 27th were given a $0.27 dividend. This represents a $1.08 annualized dividend and a yield of 0.49%. The ex-dividend date of this dividend was Friday, December 27th. Danaher’s dividend payout ratio is presently 20.45%.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the company. KeyCorp increased their target price on Danaher from $290.00 to $310.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 23rd. TD Cowen upped their target price on shares of Danaher from $310.00 to $315.00 and gave the stock a “buy” rating in a research report on Wednesday, October 23rd. Scotiabank initiated coverage on shares of Danaher in a research report on Monday, December 23rd. They set a “sector perform” rating and a $265.00 price target for the company. Wolfe Research upgraded shares of Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 price objective on the stock in a report on Thursday, October 31st. Finally, Stephens reissued an “overweight” rating and issued a $315.00 price target on shares of Danaher in a research report on Wednesday, October 23rd. Seven investment analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. According to data from MarketBeat, Danaher has a consensus rating of “Moderate Buy” and an average price target of $278.00.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.